



85. (New) The method of claim 84, wherein the B lymphocyte is an activated B lymphocyte.

86. (New) The method of claim 85, wherein the activated B lymphocyte is a splenic activated B lymphocyte.

87. (New) The method of claim 82, wherein the antigen-presenting cell is a lymphoid cell.

88. (New) The method of claim 82, wherein the antigen-presenting cell is a peripheral blood lymphocyte.

89. (New) The method of claim 82, wherein the antigen-presenting cell is a bone marrow lymphocyte.

90. (New) The method of claim 82, wherein the antigen-presenting cell is a Langerhans cell.

91. (New) The method of claim 82, wherein the antigen-presenting cell is a dendritic cell.

92. (New) The method of claim 82, wherein the anti-gp39 antibody is an anti-human anti-gp39 antibody.

93. (New) The method of claim 92, wherein the anti-human anti-gp39 antibody is humanized.

94. (New) The method of claim 92, wherein the anti-human anti-gp39 antibody is a chimeric anti-human anti-gp39 antibody containing human constant regions.